Omeros (OMER) Income from Continuing Operations (2010 - 2026)
Omeros (OMER) posted Income from Continuing Operations of 51249000.0 for Q1 2026, up 247.3% sequentially from 34792000.0 in Q4 2025, and up 236.43% YoY from 15233295.76 in Q1 2025.
Powered by 
Analysis
Omeros (OMER) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Omeros has reported Income from Continuing Operations for 17 years, with the latest figure at 51249000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 236.43% year-over-year to 51249000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74949000.0 (up 56.93% YoY) and the FY2025 annual result came in at 4808000.0, up 97.37% from the prior year.
- Income from Continuing Operations improved to 51249000.0 in Q1 2026 per OMER's latest filing, from 34792000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 51249000.0 in Q1 2026 and troughed at 65125000.0 in Q2 2024.
- A 5-year average of 38316294.12 and a median of 41695000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations tumbled 141.34% in 2022, then soared 236.43% in 2026.
- Over 5 years, Income from Continuing Operations stood at 27608000.0 in 2022, then slumped by 111.24% to 58319000.0 in 2023, then jumped by 44.97% to 32092000.0 in 2024, then dropped by 8.41% to 34792000.0 in 2025, then surged by 247.3% to 51249000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 51249000.0, 34792000.0, and 47428000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 6.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.64 Mn |
| Mar 31, 2026 | 51.25 Mn |
| Dec 31, 2025 | -36.69 Mn |
| Sep 30, 2025 | -12.42 Mn |
| Jun 30, 2025 | -25.89 Mn |
| Mar 31, 2025 | -37.57 Mn |
| Dec 31, 2024 | -34.26 Mn |
| Sep 30, 2024 | -37.11 Mn |
| Jun 30, 2024 | -65.13 Mn |
| Mar 31, 2024 | -43.85 Mn |
| Dec 31, 2023 | -43.40 Mn |
| Sep 30, 2023 | -51.66 Mn |
| Jun 30, 2023 | -44.29 Mn |
| Mar 31, 2023 | -39.68 Mn |
| Dec 31, 2022 | -46.05 Mn |
| Sep 30, 2022 | -54.79 Mn |
| Jun 30, 2022 | -41.70 Mn |
| Mar 31, 2022 | -39.49 Mn |
| Dec 31, 2021 | -105.16 Mn |
| Sep 30, 2021 | -22.70 Mn |